Patient and disease characteristics in DTFL, LSTFL, and ASTFL cohorts
| DTFL (n = 38) . | LSTFL (n = 17) . | ASFL (n = 241) . | |||
|---|---|---|---|---|---|
| Age median (range) | 57 (22-84) | 61 (33-85) | 59 (27-83) | ||
| Sex | |||||
| Male | 13 (34%) | 5 (29%) | 127 (53%) | ||
| Localization | Stage | Stage | |||
| Duodenum | 22 | I | 12 | I | 0 |
| Jejunum or ileum | 10 | II | 5 | II | 0 |
| Colon or rectum | 5 | III | 0 | III | 91 |
| Unknown | 1 | IV | 0 | IV | 150 |
| Treatment | Treatment | Treatment | |||
| RT | 12 | RT | 9 | R-CHOP | 137 |
| Rituximab mono | 4 | Rituximab mono | 1 | R-CVP | 104 |
| R-chemo | 3 | R-chemo | 3 | ||
| Surgery | 4 | Surgery | 1 | ||
| No treatment or unknown | 17 | RT + systemic treatment | 2 | ||
| No treatment | 1 | ||||
| DTFL (n = 38) . | LSTFL (n = 17) . | ASFL (n = 241) . | |||
|---|---|---|---|---|---|
| Age median (range) | 57 (22-84) | 61 (33-85) | 59 (27-83) | ||
| Sex | |||||
| Male | 13 (34%) | 5 (29%) | 127 (53%) | ||
| Localization | Stage | Stage | |||
| Duodenum | 22 | I | 12 | I | 0 |
| Jejunum or ileum | 10 | II | 5 | II | 0 |
| Colon or rectum | 5 | III | 0 | III | 91 |
| Unknown | 1 | IV | 0 | IV | 150 |
| Treatment | Treatment | Treatment | |||
| RT | 12 | RT | 9 | R-CHOP | 137 |
| Rituximab mono | 4 | Rituximab mono | 1 | R-CVP | 104 |
| R-chemo | 3 | R-chemo | 3 | ||
| Surgery | 4 | Surgery | 1 | ||
| No treatment or unknown | 17 | RT + systemic treatment | 2 | ||
| No treatment | 1 | ||||
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; R, rituximab.